Powder: -20°C for 3 years
In solvent: -80°C for 2 years
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
Description | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
Targets&IC50 | G2019S LRRK2:1.85 nM, LRRK2 wild-type:1.28 nM |
Cell Research | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
Synonyms | CCG1423, CCG 1423 |
Molecular Weight | 454.75 |
Formula | C18H13ClF6N2O3 |
CAS No. | 285986-88-1 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 4 mg/mL (8.79 mM), warmed
H2O: <1 mg/mL
DMSO: 83 mg/mL (182.5 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG-1423 285986-88-1 G蛋白偶联受体 MAPK信号通路 细胞周期 自噬 LRRK2 Ras Rho PC-3 conformational restriction mice Inhibitor bioisostere CCG1423 glucose tolerance CCG 1423 metastasis Apoptosis inhibit prostate,serum inhibitor